LEGN · Legend Biotech Corp · Webcasts, Transcripts & Audio
Market Cap
$3.72B
Shares
194.49M
Volume · Oct 1
2.22M
Avg daily vol (3M)
2.33M
Legend Biotech Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Legend Biotech Corp (LEGN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲158.7%
$93.99M
−$59.79M
'24 Q1
24-03-31
·
$160.21M
−$125.32M
'24 Q3
24-09-30
·
$186.52M
$26.28M
'24 Q4
24-12-31
▲107.5%
$195.00M
−$100.92M
'25 Q1
25-03-31
▲36.8%
$255.10M
−$125.40M
'25 Q2
25-06-30
▲70%
$272.33M
−$39.69M
'25 Q3
25-09-30
▲56.5%
$305.10M
−$54.30M
'26 Q1
26-05-12
LATEST
▲51.9%
$387.50M
$33.20M
'26 Q2
26-08-11
Earnings call
FY26 · Q2
2026-08-11
Legend Biotech Corp (LEGN) Q2 2026 Earnings Call
Revenue
$387.50M
▲ 51.9% YoY Diluted EPS
$0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Transcript
Confident tone
In Vivo cell therapy pipeline
Earlier-line / frontline opportunity
CARVYKTI commercial growth
Revenue
$305.10M
▲ 56.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Legend Biotech Corp (LEGN) Q3 2025 Earnings Call Transcript
Confident tone
ASH 2025 presentations
Regulatory and label updates
Manufacturing capacity expansion
Revenue
$272.33M
▲ 70% YoY Diluted EPS
$-0.11
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Transcript
Confident tone
CARVYKTI commercial performance
CARTITUDE clinical trials and frontline expansion
FDA REMS removal and label update
Revenue
$255.10M
▲ 36.8% YoY Diluted EPS
$-0.34
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Transcript
Confident tone
CARVYKTI commercial performance
Earlier-line adoption and label expansion
Manufacturing capacity and turnaround time
Revenue
$195.00M
▲ 107.5% YoY Diluted EPS
$-0.27
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Transcript
Confident tone
CARVYKTI commercial launch and sales growth
Manufacturing and capacity expansion
ALC monitoring and risk mitigation
Revenue
$186.52M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Legend Biotech Corp (LEGN) Q3 2024 Earnings Call Transcript
Confident tone
CARVYKTI commercial sales growth
Overall survival benefit / CARTITUDE-4
Geographic expansion (OUS)
Revenue
$160.21M
Diluted EPS
$-0.34
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript
Confident tone
Commercial launch and demand growth
Manufacturing capacity expansion and supply
CARVYKTI regulatory approvals and label expansion
Revenue
$93.99M
▲ 158.7% YoY Diluted EPS
$-0.16
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Legend Biotech Corp (LEGN) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Legend Biotech Corp (LEGN) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Legend Biotech Corp (LEGN) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Legend Biotech Corp (LEGN) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–12 of 12 webcasts